Ketamine + Methohexital for Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how different anesthesia medications, Ketamine and Methohexital, affect brain waves during electroconvulsive therapy (ECT) for depression. Researchers specifically examine slow-wave changes in the brain using a tool called dcEEG. The trial targets individuals diagnosed with major depressive disorder (MDD) or bipolar disorder (BPD) who require ECT due to treatment resistance or a need for quick results. Those with depression characterized by frequent and severe symptoms might be suitable for this study. As an Early Phase 1 trial, this research aims to understand how these anesthesia medications work in people, offering participants a chance to contribute to groundbreaking insights.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that ketamine, a drug often used to induce sleep during surgery, can have side effects affecting the brain, spinal cord, heart, and blood vessels. Some individuals might also experience breathing issues, such as throat muscle spasms.
Methohexital, another drug used for the same purpose, is generally safe when administered by a doctor. It has been used for many years and is well-known in hospitals.
Although both drugs can cause side effects, they are usually well-tolerated in controlled settings like hospitals. This trial is in its early stages and aims to assess the safety of these treatments. As a result, the existing safety information might still be limited.12345Why are researchers excited about this trial's treatments?
Most treatments for depression using electroconvulsive therapy (ECT) involve anesthesia like methohexital, which doesn't alter brain wave patterns. However, ketamine is unique because it suppresses slow wave characteristics in the brain. This feature potentially enhances ECT's effects and allows for a quicker response in treating depressive symptoms. Researchers are excited because ketamine could offer a faster and possibly more effective way to enhance ECT outcomes, providing hope for improved treatment experiences.
What evidence suggests that this trial's treatments could be effective for depression?
Research has shown that ketamine, one of the treatments studied in this trial, can reduce symptoms of depression. In some studies, participants experienced a significant drop in depression levels just days after receiving ketamine treatment. Ketamine also helps manage post-surgical pain, potentially reducing the need for other pain medications. In contrast, methohexital, another treatment option in this trial, is a common anesthetic used to induce sleep during procedures but does not specifically target brain activity related to depression. While methohexital is effective for anesthesia, ketamine offers unique benefits for those with depression.678910
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive electroconvulsive therapy (ECT) with either ketamine or methohexital as the anesthesia induction agent, and dcEEG data is collected
Follow-up
Participants are monitored for cognitive performance and clinical efficacy of ECT
What Are the Treatments Tested in This Trial?
Interventions
- Ketamine
- Methohexital
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Standard of care anesthesia that suppresses slow wave characteristics
Standard of care anesthesia that does not affect slow wave characteristics
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of New Mexico
Lead Sponsor
Citations
Ketamine - StatPearls - NCBI Bookshelf - NIH
Ketamine is highly effective for brief medical procedures that do not necessitate skeletal muscle relaxation and can be utilized as a pre- ...
Efficacy and safety of ketamine as an adjuvant to regional ...
Ketamine as an adjuvant to regional anesthesia prolongs the duration of analgesia about 3 h while in peripheral nerve block about 6 h.
Efficacy and safety of perioperative application of ketamine ...
In conclusion, perioperative application of ketamine reduces postoperative depression and pain scores with increased risk of adverse effects.
Ketamine—From an Anesthetic to a Psychiatric Drug
Perioperative subanesthetic doses of ketamine were effective in postoperative pain control, reducing opioid requirements, while displaying minimal adverse ...
Randomized Trial of Ketamine Masked by Surgical ...
The primary outcome was the MADRS score measured 1, 2, and 3 days post-infusion, as previous studies have found the greatest antidepressant ...
SAFETY DATA SHEET
May be harmful in contact with skin. May be harmful if inhaled. 4 / 8. Material name: Ketamine Hydrochloride Injection. 255 Version #: 01 Issue ...
Material Safety Data Sheet
May be harmful if absorbed through the skin. Harmful if swallowed (based on animal data) . Known Clinical Effects: Ketamine is an anesthetic agent which is ...
SAFETY DATA SHEET
Other Hazards. Short Term: Anesthetic drug: may cause central nervous system and cardiovascular system May cause eye irritation. May be harmful if absorbed ...
ketamine - accessdata.fda.gov
The onset of action of KETALAR is rapid; an intravenous dose of 2 mg/kg of body weight usually produces surgical anesthesia within 30 seconds after injection, ...
SAFETY DATA SHEET
VetaKet® (ketamine hydrochloride injection, USP) ... Laryngospasms and other forms of airway obstruction have occurred during ketamine anesthesia.
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.